课题基金 / 基金详情

Cell Signaling and Metabolism

Cell Signaling and Metabolism
细胞信号传导和代谢
批准号:
10025017
负责人:
DAVID R ROWLEY
金额:
$4.03万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
未结题
起止时间:
2007-07-01 至 2025-06-30

项目摘要

项目成果

DAVID R ROWLEY的其他基金

相似基金

相关文献

中文摘要
翻译
细胞信号传导和代谢(CSM)研究项目总结 更名后的细胞信号传导和代谢(CSM)计划包括三个中心主题:新目标 发现主题,癌症代谢主题,细胞信号和微环境主题。的 该计划的科学目标是通过使用多组学平台更好地了解癌症生物学, 以确定和评估新的目标的机会和治疗方法。该计划已 通过整合基因组和表观基因组去卷积,在新发现方面具有相当大的实力 方法,再加上代谢组学,为推定的信号通路提供信息。该计划有40 研究成员、23名临床成员、7名兼职成员和3名共享成员,他们通过专题小组会议进行互动 疾病工作组。成员代表16个基础科学和临床部门,包括 分子和人类遗传学,生物化学和分子生物学,分子和细胞生物学,病理学 免疫学、分子生理学和生物物理学、医学、儿科学、外科学和产科学, 妇科成员专注于多种不同的癌症类型,包括胰腺,胃肠道,肝脏,肺, 前列腺癌、膀胱癌和头颈癌。在上一个预算年度,CSM计划有一个总的直接 资金1420万美元,其中包括NCI资金420万美元,其他NIH研究所200万美元,470万美元 直接来自其他同行审查资金,340万美元直接来自其他非同行审查资金。期间 在过去的5年里,项目成员共发表了706篇稿件,其中24%来自内部, 方案合作占18%,方案间合作占73%,机构间合作占73%。几 出版物和联合资助是成员之间加强沟通努力的结果, 专题分组互动。特别是,已经作出了相当大的努力,今后的计划包括利用 多组学方法来鉴定由代谢产物告知的可靶向改变的信号传导途径 审讯这包括一个重点,以确定泛癌症的变化。这些努力也是基于集水 特别是吸烟和肥胖问题。此外,还作出了相当大的努力, 生物学机制是医疗保健差异的基础。未来的方向包括扩大正式职业 通过加强沟通和方案,加强和培训生教育工作。具体目标是:1。 确定和表征重叠的分子基础和代谢调节途径, 重新布线以描绘与癌症发作和进展相关的关键共同分子介质。2.到 评估可操作的信号传导途径和生物靶点,这些靶点是代谢的因果关系或结果, 癌症进展的分子介质。3.通过与专家的互动, 药物发现中心,治疗创新中心和疾病工作组,以促进 开发新的诊断、预后和治疗方法。
英文摘要
CELL SIGNALING AND METABOLISM (CSM) PROGRAM PROJECT SUMMARY The renamed Cell Signaling and Metabolism (CSM) Program incorporates three central Themes; New Target Discovery Theme, Cancer Metabolism Theme, and the Cell Signaling and the Microenvironment Theme. The scientific goals of the Program are to better understand cancer biology through use of multi-omics platforms in order to identify and assess new targets of opportunity and therapeutic approaches. The Program has considerable strength in new discovery through integration of genomic and epigenomic deconvolution approaches, coupled together with metabolomics to inform on putative signaling pathways. The Program has 40 Research members, 23 Clinical, 7 Adjunct and 3 Shared members who interact via thematic subgroup meetings and the Disease Working Groups. Members represent 16 basic science and clinical departments, including Molecular and Human Genetics, Biochemistry and Molecular Biology, Molecular and Cellular Biology, Pathology and Immunology, Molecular Physiology and Biophysics, Medicine, Pediatrics, Surgery, and Obstetrics and Gynecology. Members focus on multiple different cancer types including pancreas, gastrointestinal, liver, lung, prostate, bladder, and head and neck cancers. During the last budget year, the CSM Program had a total direct funding of $14.2 million that included $4.2 million in NCI funding, $2 million from other NIH institutes, $4.7 million direct in other peer-reviewed funding, and $3.4 million direct from other non-peer reviewed funding. During the previous 5 years, Program members have published a total of 706 manuscripts with 24% resulting from intra- programmatic collaborations, 18% inter-programmatic, and 73% from inter-institutional collaborations. Several publications and joint funding have resulted from an enhanced communication effort between members via thematic subgroup interactions. In particular, considerable effort has been made and future plans include use of multi-omic approaches to identify targetable altered signaling pathways that are informed by metabolic interrogation. This includes a focus to identify pan-cancer alterations. These efforts are also based on catchment area issues, including smoking and obesity, in particular. In addition, considerable effort is focused on identifying biological mechanisms that underlie health care disparity. Future directions include expanding formal career enhancement and trainee educational efforts via enhanced communication and programs. Specific Aims are: 1. To identify and characterize the overlapping molecular underpinnings and pathways regulating metabolic rewiring to delineate key common molecular mediators associated with cancer onset and progression. 2. To evaluate actionable signaling pathways and biological targets that are causal or a consequence of metabolic and molecular mediators of cancer progression. 3. To enact translation of key findings through interactions with the Center for Drug Discovery, the Therapeutic Innovation Center, and the Disease Working Groups to foster development of novel diagnostic, prognostic, and therapeutic approaches.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Osteogenic Niche Biology in Progression and Endocrine Resistance of Bone Metastases
  • 批准号:
    10474332
  • 项目类别:
  • 资助金额:
    $47.91万
  • 财政年份:
    2018
  • 负责人:
    DAVID R ROWLEY
  • 依托单位:
Osteogenic Niche Biology in Progression and Endocrine Resistance of Bone Metastases
  • 批准号:
    10231044
  • 项目类别:
  • 资助金额:
    $48.89万
  • 财政年份:
    2018
  • 负责人:
    DAVID R ROWLEY
  • 依托单位:
Osteogenic Niche Biology in Progression and Endocrine Resistance of Bone Metastases
  • 批准号:
    10001465
  • 项目类别:
  • 资助金额:
    $48.89万
  • 财政年份:
    2018
  • 负责人:
    DAVID R ROWLEY
  • 依托单位:
SUMMER UNDERGRADUATE RESEARCH FELLOWSHIP PROGRAM
  • 批准号:
    8360067
  • 项目类别:
  • 资助金额:
    $39.34万
  • 财政年份:
    2011
  • 负责人:
    DAVID R ROWLEY
  • 依托单位:
海外基金